Program
pentanedioic acid imidazolyl ethanamide
Also written as “Ingavirin”, “Ingavirin, capsules, 90 mg” and “Ingavirin®”.
Its studies are mostly in Influenza, Human · Common Cold · COVID-19 · Breast Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Valenta Pharm JSC | 92 open or running | phase 4since Apr 26, 2017 | Dec 22, 2015 | Dec 31, 2027phase 1 · NCT07645534 |
| Myelo Therapeutics | 10 open or running | phase 2since Feb 23, 2016 | Feb 23, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 22, 2015First study: phase 3 study in Common ColdNew to Valenta Pharm JSCValenta Pharm JSC · NCT02644018 · 190 enrolled · Russian Federation
- Feb 23, 2016Myelo Therapeutics’ first study: phase 2 study in Breast NeoplasmsNew to Myelo TherapeuticsMyelo Therapeutics · NCT02692742 · 137 enrolled · Germany
- Apr 26, 2017Phase 4 study in Common ColdValenta Pharm JSC · NCT03154515 · 445 enrolled · Russian Federation
- Jun 8, 20173 phase 3 studies in Influenza, HumanValenta Pharm JSC · NCT03189537, NCT03191097, NCT03206346
- Jan 28, 20222 phase 3 studiesValenta Pharm JSC · NCT05269290, NCT05216497
- Mar 11, 2024Phase 4 study in Influenza, HumanValenta Pharm JSC · NCT06315400 · 80 planned · Russian Federation
- May 12, 2026Phase 1 study in Influenza, HumanValenta Pharm JSC · NCT07645534 · 36 planned · Russia
Ahead
- Dec 31, 2027Primary completion: phase 1 study in Influenza, HumanValenta Pharm JSC · NCT07645534
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07645534Influenza, Human · Russia | 1 | Recruiting | Valenta Pharm JSC | Dec 31, 2027 | 36 |
| NCT06315400Influenza, Human · Russian Federation | 4 | Recruiting | Valenta Pharm JSC | Dec 31, 2025 | 80 |
| NCT05269290Influenza, Human · Russian Federation | 3 | Completed | Valenta Pharm JSC | Apr 29, 2022 | 240 |
| NCT05216497COVID-19 · Russian Federation | 3 | Completed | Valenta Pharm JSC | Jan 12, 2022 | 233 |
| NCT03206346Influenza, Human · Russian Federation | 3 | Completed | Valenta Pharm JSC | Nov 2012 | 161 |
| NCT03191097Influenza, Human · Russian Federation | 3 | Completed | Valenta Pharm JSC | Dec 2014 | 310 |
| NCT03189537Influenza, Human · Russian Federation | 3 | Completed | Valenta Pharm JSC | Apr 19, 2011 | 400 |
| NCT03154515Common Cold · Russian Federation | 4 | Completed | Valenta Pharm JSC | Apr 2014 | 445 |
| NCT02692742Breast Neoplasms · Germany | 2 | Completed | Myelo Therapeutics | Nov 2017 | 137 |
| NCT02644018Common Cold · Russian Federation | 3 | Completed | Valenta Pharm JSC | May 2016 | 190 |
How it is read
Names in the registry
- “Ingavirin”, 3 entries
- “Ingavirin, capsules, 90 mg”, 1 entry
- “Ingavirin®”, 1 entry
- “Ingavirin®, syrup, 30 mg/5 ml”, 1 entry
- “Ingavirin®, 90 mg capsules”, 1 entry
Conditions, from the studies’ own filings
- Influenza, Human, 6 studies
- Common Cold, 2 studies
- COVID-19, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.